

CONSOLIDATED					Sr.No.	Particulars	COMPANY				
Rupees in Millions							Rupees in Millions				
For the quarter ended on December 31,		Nine Months period ended on December 31,		Previous Accounting year ended			For the quarter ended on December 31,		Nine Months period ended on December 31,		Previous Accounting year ended
2006	2005	2006	2005	on March 31, 2006	2006	2005	2006	2005	on March 31, 2006		
				[Audited]					[Audited]		
4815	3869	#####	11577	15078	1	Sales & Income from operations :					
206	174	628	488	625	A	Gross Sales	3749	3328	11561	10178	13082
4609	3695	#####	11089	14453	B	Less : Excise Duty	205	172	625	486	622
115	83	287	296	392	C	Net Sales	3544	3156	10936	9692	12460
4724	3778	#####	11385	14845	D	Other Income from Operations	172	76	336	292	377
196	44	249	45	36	E	Total sales and other income from operations	3716	3232	11272	9984	12837
4920	3822	#####	11430	14881	2	Other Income	109	103	321	329	379
					3	Total Income	3825	3335	11593	10313	13216
					4	Expenditure :					
(32)	(101)	(524)	(167)	(99)	A	Increase / Decrease [-] in Stock in Trade	(64)	(103)	(402)	(186)	(52)
1715	1500	5374	4458	5787	B	Consumption of Materials	1413	1367	4425	4016	5142
519	495	1511	1363	1804	C	Staff Cost	430	420	1257	1156	1529
1699	1151	4760	3510	4476	D	Other Expenditure	1215	917	3755	3010	3777
3901	3045	#####	9164	11968	E	Total Expenditure	2994	2601	9035	7996	10396
1019	777	3059	2266	2913	5	Profit before Interest , Depreciation & Tax	831	734	2558	2317	2820
45	49	169	143	194	6	A Interest & Financial Charges	40	37	136	107	148
4	54	2	72	57	B	Exchange Rate Fluctuations on Foreign Currency L	4	54	2	72	57
49	103	171	215	251	C	Total Financial cost	44	91	138	179	205
970	674	2888	2051	2662	7	Profit before Depreciation & Tax	787	643	2420	2138	2615
212	214	623	585	779	8	Depreciation & Amortisation	172	153	498	453	616
758	460	2265	1466	1883	9	Profit before Tax & Exceptional Items	615	490	1922	1685	1999
0	14	0	89	115	10	Less : Exceptional Items	0	13	0	86	111
758	446	2265	1377	1768	11	Profit before tax	615	477	1922	1599	1888
					12	Provision for Taxation :					
85	22	201	103	131	A	Current Tax	77	22	177	103	130
0	24	50	61	87	B	Deferred Tax	0	23	50	60	85
13	3	23	10	15	C	Fringe Benefit Tax	13	3	23	10	15
0	0	0	0	10	D	Prior Year Tax Adjustments	0	0	0	0	9
98	49	274	174	243	E	Total provision for taxation	90	48	250	173	239
660	397	1991	1203	1525	13	Profit after tax	525	429	1672	1426	1649
(1)	(1)	(42)	15	(1)	14	Adjustments on consolidation	0	0	0	0	0
659	396	1949	1218	1524	15	Net Profit	525	429	1672	1426	1649
628	314	628	314	314	16	Paid up Equity Share Capital [Face Value Rs. 5 /-	628	314	628	314	314
					17	Reserves excluding Revaluation Reserve					7049
					18	E P S [Rs.] [For the period - not Annualised]:					
5.25	3.26	15.52	10.40	13.05	a	Before extra-ordinary items	4.18	3.52	13.31	12.04	14.01
5.25	3.15	15.52	9.70	12.13	b	After extra-ordinary items	4.18	3.42	13.31	11.35	13.13
					19	Aggregate of Non-promoter Shareholding :					
						- Number of Equity Shares	4E+07	1.8E+07	4E+07	1.8E+07	17575229
						- Percentage of Shareholding	27.98%	27.98%	27.98%	27.98%	27.98%

Notes :

- [1] The above results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on January 22, 2007 and the statutory auditors of the Company have carried out a limited review of the financial results of the Company.
- [2] During the quarter, USFDA has approved two more ANDAs filed by the Company.
- [3] [A] The Company has made investments in Shares of the following Group Companies during the quarter :
- | <u>Name of the Concern</u> | <u>Rs. In Millions</u> |
|--|------------------------|
| Zydus International Pvt. Ltd., [Wholly owned subsidiary] | 40.47 |
| Zydus Mayne Oncology Pvt. Ltd. [Joint venture] | 50 |
| Zydus BSV Pharma Pvt. Ltd. [joint Venture] | 12.5 |
- [B] The company has subscribed Rs. 165.9 millions to the capital of M/s. Zydus Healthcare, a partnership firm in which the Company is a partner.
- [4] During the quarter, " Zydus Netherlands B.V. ", a new company has been formed in Netherlands.
- [5] The status of investor complaints :
- Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 44, pending at the end of the quarter - Nil.
- [6] The Company has one segment of activity viz. " Pharmaceuticals ".

By Order of the Board,
For Cadila Healthcare Limited,

Pankaj R.Patel
Chairman & Managing Director